The Fly | TCRT

Proprietary Non-Viral Gene Transfer Technology: Alaunos utilizes a unique, non-viral method for engineering T-cells, potentially offering a safer, more efficient, and more scalable approach compared to traditional viral vector-based gene delivery systems.

Specialized Focus on Solid Tumors: The company is dedicated to developing TCR-T cell therapies specifically for solid tumors, a challenging but vast market segment with significant unmet medical need where current cell therapies have had limited success.

High-Affinity TCR Identification Platform (hunTR): Their proprietary hunTR platform is designed to discover and validate high-affinity T-cell receptors that can precisely target tumor-specific antigens, enhancing therapeutic potency and specificity.

Clinical Trial Success Uncertainty: Alaunos Therapeutics' future success heavily depends on the successful development, clinical trials, and regulatory approval of its T-cell receptor (TCR) engineered T-cell therapies.

Regulatory Approval Risk: Even if clinical trials demonstrate efficacy and safety, there is no guarantee that regulatory authorities like the FDA will grant approval for their product candidates, or that such approval will be timely.

Significant Funding Needs and Dilution Risk: As a clinical-stage company without product revenue, Alaunos Therapeutics requires substantial additional capital to fund its operations, which may lead to further equity offerings and significant dilution for existing shareholders.